Virtual ISPOR 2021

Gold sponsor

May 2021

Carelon Research is a proud sponsor of Virtual ISPOR 2021! Visit our exhibit, live chat with our presenting authors, and see our latest research. Posters and exhibits are viewable Monday through Thursday from 10:00 AM until 4:00 PM EDT.

This year’s conference, focused on HEOR: evolving for tomorrow’s challenges, addresses challenging questions with on demand-only content and a 4-day live conference schedule tailored to a global audience. For more information, please visit ispor.org Registration is required.

Carelon Research presentations

Carelon Research authors are indicated in bold.

Presentation	Session	Title	Authors	Affiliations
Virtual Poster Discussion Session 1 Monday, May 17 12:45 – 3:00 PM EDT LIVE chat with Dr. Michael Grabner 2:00 – 3:00 PM EDT	Biologics/biosimilars/regenerative medicine (PBI) – economic evaluation	PBI12 \| Healthcare resource utilization and costs in patients with psoriasis who switched to biologic or phosphodiesterase 4 inhibitor therapies due to inadequate response	Curtis J¹, Grabner M², Burge RT^3,4, Teng CC², Shan M³, Garrelts A³, Ridenour T³, Isenberg K⁵	¹University of Alabama at Birmingham, Birmingham, AL, ²Carelon Research, Wilmington, DE, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Cincinnati, Cincinnati, OH, USA, ⁵Elevance Health, Indianapolis, IN, USA
Virtual Poster Discussion Session 1 Monday, May 17 12:45 – 3:00 PM EDT	Cardiovascular disorders (PCV) – economic evaluation	PCV35 \| Costs of septal reduction therapy for obstructive hypertrophic cardiomyopathy: a US claims analysis	Butzner M¹, Sarocco P¹, Maron M², Rowin E², Teng CC³, Stanek E³, Tan H³, Robertson L¹	¹Cytokinetics, Inc., South San Francisco, CA, ²Hypertrophic Cardiomyopathy Center and Research Institute, Tufts Medical Center, Boston, MA, ³Carelon Research, Wilmington, DE
Virtual Poster Discussion Session 1 Monday, May 17 12:45 – 3:00 PM EDT	Multiple diseases (PMU) – methodological & statistical research	PMU54 \| A claims-based algorithm to identify inadequate response to immunomodulatory therapies among patients with selected autoimmune diseases	Grabner M¹, Hunter T², Teng CC¹, Isenberg K³, Burge R², Birt J², Naegeli A², Shan M², Curtis JR⁴	¹Carelon Research, Wilmington, DE, ²Eli Lilly and Company, Indianapolis, IN, ³Elevance Health, Indianapolis, IN, ⁴University of Alabama at Birmingham, Birmingham, AL
Virtual Poster Discussion Session 2 Tuesday, May 18 11:30 AM – 1:45 PM EDT LIVE chat with Dr. Michael Grabner 12:00 – 1:00 PM EDT	Individual’s health (PIH) – economic evaluation	PIH7\| Cost-effectiveness of a proteomic test for preterm birth prediction	Grabner M¹, Burchard J², Nguyen C¹, Chung H¹, Gangan N¹, Boniface JJ², Zupancic JAF³, Stanek E¹	¹Carelon Research, Wilmington, DE, ²Sera Prognostics, Salt Lake City, UT, ³Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, MA

Gold sponsor

Carelon Research presentations

Ready to learn more? Let's connect.